From sepsis to necrotizing enterocolitis with appendiceal perforation: a case report of successful salvage therapy with aztreonam–avibactam in an extremely preterm infant with NDM-producing Klebsiella pneumoniae
5 affiliations
- 1Department of Pediatrics, West China Second University Hospital, Sichuan University
- 2Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
- 3Department of Neurology and State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University
- 4Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University
- 5Department of Pediatric General Surgery, West China Second University Hospital, Sichuan University
Abstract
Infections caused by New Delhi metallo-β-lactamase (NDM)-producing Klebsiella pneumoniae represent a major therapeutic challenge in neonatology, particularly in extremely preterm infants, for whom effective options are limited and dosing and safety data for last-resort agents such as aztreonam-avibactam remain scarce. We report the case of a male infants born at 24 ⁺² weeks of gestation with a birth weight of 530 g who developed Klebsiella pneumoniae sepsis with poor clinical response to aztreonam combined with polymyxin B. His clinical course was complicated by pulmonary hemorrhage, disseminated intravascular coagulation, necrotizing enterocolitis, appendiceal perforation, and suspected necrotizing fasciitis. Blood and ascitic fluid metagenomic next-generation sequencing (mNGS) identified NDM-producing carbapenem-resistant K. pneumoniae . Given the lack of effective alternatives and ongoing clinical deterioration, off-label intravenous aztreonam-avibactam was initiated as salvage therapy. Marked clinical improvement was observed within 4 days after aztreonam-avibactam treatment, blood mNGS converted to negative by day 6, and skin and gastrointestinal manifestations resolved after 10 days of treatment, and no adverse events considered attributable to aztreonam-avibactam were identified. This case suggests that aztreonam-avibactam may be a viable salvage option for life-threatening NDM-producing K. pneumoniae infections in extremely preterm infants, though prospective pharmacokinetic and safety data in this population are urgently warranted.
Related
- Necrotizing Enterocolitis Secondary to Congenital Syphilis in an 18-Day-Old Neonate: Successful Treatment With Intravenous Penicillin.
- A case of neonatal gastric perforation misdiagnosed as neonatal necrotizing enterocolitis: A literature review.
- Valentino's syndrome with secondary appendiceal perforation and fungal involvement.
- Advances in fecal biomarkers for necrotizing enterocolitis
- AhR ligands in necrotizing enterocolitis: a provisional evidence map of ligand-specific biology and translational considerations.
BibTeX
@article{he2026from,
title = {{From sepsis to necrotizing enterocolitis with appendiceal perforation: a case report of successful salvage therapy with aztreonam–avibactam in an extremely preterm infant with NDM-producing Klebsiella pneumoniae}},
author = {Yang He and Jichong Huang and Bin Du and Zhe Chen and Liang Huang and Jing Shi and Min Zhang and Li Zhang and Jun Tang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1919037},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1919037/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From sepsis to necrotizing enterocolitis with appendiceal perforation: a case report of successful salvage therapy with aztreonam–avibactam in an extremely preterm infant with NDM-producing Klebsiella pneumoniae
AU - Yang He
AU - Jichong Huang
AU - Bin Du
AU - Zhe Chen
AU - Liang Huang
AU - Jing Shi
AU - Min Zhang
AU - Li Zhang
AU - Jun Tang
PY - 2026
DA - 2026/10/19
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1919037
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1919037/full
AB - Infections caused by New Delhi metallo-β-lactamase (NDM)-producing Klebsiella pneumoniae represent a major therapeutic challenge in neonatology, particularly in extremely preterm infants, for whom effective options are limited and dosing and safety data for last-resort agents such as aztreonam-avibactam remain scarce. We report the case of a male infants born at 24 ⁺² weeks of gestation with a birth weight of 530 g who developed Klebsiella pneumoniae sepsis with poor clinical response to aztreonam combined with polymyxin B. His clinical course was complicated by pulmonary hemorrhage, disseminated intravascular coagulation, necrotizing enterocolitis, appendiceal perforation, and suspected necrotizing fasciitis. Blood and ascitic fluid metagenomic next-generation sequencing (mNGS) identified NDM-producing carbapenem-resistant K. pneumoniae . Given the lack of effective alternatives and ongoing clinical deterioration, off-label intravenous aztreonam-avibactam was initiated as salvage therapy. Marked clinical improvement was observed within 4 days after aztreonam-avibactam treatment, blood mNGS converted to negative by day 6, and skin and gastrointestinal manifestations resolved after 10 days of treatment, and no adverse events considered attributable to aztreonam-avibactam were identified. This case suggests that aztreonam-avibactam may be a viable salvage option for life-threatening NDM-producing K. pneumoniae infections in extremely preterm infants, though prospective pharmacokinetic and safety data in this population are urgently warranted.
SN - 1663-9812
ER -